

Freeform Search

Database: US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Term:

Display: **Documents in Display Format:** CIT Starting with Number

Generate: Hit List Hit Count Side by Side Image

Search History

DATE: Wednesday, January 17, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT; PLUR=YES; OP=AND</i>			
<u>L3</u>	L2 and uvrC	31	<u>L3</u>
<u>L2</u>	L1 and uvrA or uvrB	156	<u>L2</u>
<u>L1</u>	listeria or bacillus	28975	<u>L1</u>

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
L4 and uvra adj mutation	1

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L5

Refine Search

Recall Text Clear Interrupt

Search History

DATE: Wednesday, January 17, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

Set Name

Query

Hit Count

Set Name

result set

DB=USPT; PLUR=YES; OP=AND

<u>L5</u>	L4 and uvra adj mutation	1	<u>L5</u>
<u>L4</u>	l2 and mutants	110	<u>L4</u>
<u>L3</u>	L2 and uvrC	31	<u>L3</u>
<u>L2</u>	L1 and uvrA or uvrB	156	<u>L2</u>
<u>L1</u>	listeria or bacillus	28975	<u>L1</u>

END OF SEARCH HISTORY

Sindbis virus-derived DNA vectors described here increase the utility of alphavirus-based vector systems in general and also provide a vector with broad potential applications for genetic immunization.

L2 ANSWER 24 OF 24 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 96082685 EMBASE
DN 1996082685
TI Layered amplification of gene expression with a DNA gene delivery system.
AU Driver D.A.; Latham E.M.; Polo J.M.; Belli B.A.; Banks T.A.; Chada S.; Brumm D.; Chang S.M.W.; Mento S.J.; Jolly D.J.; Dubensky Jr T.W.
CS Viagene Inc, 11055 Roselle Street, San Diego, CA 92121, United States
SO Annals of the New York Academy of Sciences, (1995) Vol. 772, pp. 261-264.

ISSN: 0077-8923 CODEN: ANYAA
CY United States
DT Journal; Conference Article
FS 004 Microbiology
022 Human Genetics
LA English
ED Entered STN: 2 Apr 1996
Last Updated on STN: 2 Apr 1996

=> e brockstedt dirk/au
E1 25 BROCKSTEDT D/AU
E2 24 BROCKSTEDT D G/AU
E3 21 --> BROCKSTEDT DIRK/AU
E4 32 BROCKSTEDT DIRK G/AU
E5 28 BROCKSTEDT E/AU
E6 11 BROCKSTEDT EKKEHARD/AU
E7 1 BROCKSTEDT F C/AU
E8 37 BROCKSTEDT H/AU
E9 1 BROCKSTEDT H C/AU
E10 2 BROCKSTEDT H J/AU
E11 51 BROCKSTEDT M/AU
E12 30 BROCKSTEDT RASMUSSEN H/AU

=> s e1-e4 and (nucleic or bacter?)
L3 43 ("BROCKSTEDT D"/AU OR "BROCKSTEDT D G"/AU OR "BROCKSTEDT DIRK"/AU OR "BROCKSTEDT DIRK G"/AU) AND (NUCLEIC OR BACTER?)

=> dup rem 13
PROCESSING COMPLETED FOR L3
L4 22 DUP REM L3 (21 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 22 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1
AN 2006:239172 BIOSIS
DN PREV200600237018
TI Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.
AU Yoshimura, Kiyoshi; Jain, Ajay; Allen, Heather E.; Laird, Lindsay S.; Chia, Christina Y.; Ravi, Sowmya; Brockstedt, Dirk G.; Giedlin, Martin A.; Bahjat, Keith S.; Leong, Meredith L.; Slansky, Jill E.; Cook, David N.; Dubensky, Thomas W.; Pardoll, Drew M.; Schulick, Richard D. [Reprint Author]
CS Johns Hopkins Med Inst, Dept Surg and Oncol, Bunting Blaustein Canc Res Bldg, Suite 442, 1650 Or, Baltimore, MD 21231 USA
rschulick@jhmi.edu

=> e dubensky jr thomas/au
E1 5 DUBENSKY HAROLD J/AU
E2 8 DUBENSKY JR T W/AU
E3 0 --> DUBENSKY JR THOMAS/AU
E4 16 DUBENSKY JR THOMAS W/AU
E5 1 DUBENSKY M/AU
E6 2 DUBENSKY M M/AU
E7 2 DUBENSKY M S/AU
E8 3 DUBENSKY M W/AU
E9 5 DUBENSKY R/AU
E10 5 DUBENSKY R A/AU
E11 7 DUBENSKY R G/AU
E12 1 DUBENSKY RICHIE/AU

=> s e2-e4
L1 24 ("DUBENSKY JR T W"/AU OR "DUBENSKY JR THOMAS"/AU OR "DUBENSKY JR THOMAS W"/AU)

=> dup rem 11
PROCESSING COMPLETED FOR L1
L2 24 DUP REM L1 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 24 ANSWERS - CONTINUE? Y/(N):y

L2 ANSWER 1 OF 24 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 2005375886 EMBASE
TI Killed but metabolically active microbes: A new vaccine paradigm for eliciting effector T-cell responses and protective immunity.
AU Brockstedt D.G.; Bahjat K.S.; Giedlin M.A.; Liu W.; Leong M.; Luckett W.; Gao Y.; Schnupf P.; Kapadia D.; Castro G.; Lim J.Y.H.; Sampson-Johannes A.; Herskovits A.A.; Stassinopoulos A.; Bouwer H.G.A.; Hearst J.E.; Portnoy D.A.; Cook D.N.; Dubensky Jr. T.W.
CS T.W. Dubensky Jr., Cerus Corporation, 2411 Stanwell Drive, Concord, CA 94520, United States. tom_dubensky@cerus.com
SO Nature Medicine, (2005) Vol. 11, No. 8, pp. 853-860. .
Refs: 46
ISSN: 1078-8956 CODEN: NAMEFI
CY United Kingdom
DT Journal; Article
FS 004 Microbiology
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English
ED Entered STN: 22 Sep 2005
Last Updated on STN: 22 Sep 2005
AB We developed a new class of vaccines, based on killed but metabolically active (KBMA) bacteria, that simultaneously takes advantage of the potency of live vaccines and the safety of killed vaccines. We removed genes required for nucleotide excision repair (uvrAB), rendering microbial-based vaccines exquisitely sensitive to photochemical inactivation with psoralen and long-wavelength ultraviolet light. Colony formation of the nucleotide excision repair mutants was blocked by infrequent, randomly distributed psoralen crosslinks, but the bacterial population was able to express its genes, synthesize and secrete proteins. Using the intracellular pathogen Listeria monocytogenes as a model platform, recombinant psoralen-inactivated Lm ΔuvrAB vaccines induced potent CD4(+) and CD8(+) T-cell responses and protected mice against virus challenge in an infectious disease model and provided therapeutic benefit in a mouse cancer model. Microbial KBMA vaccines used either as a recombinant vaccine platform or as a modified form of the pathogen itself may have broad use for the treatment of infectious disease and cancer.

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9904632	A1	19990204	WO 1998-US15461	19980724
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2300335	AA	19990204	CA 1998-2300335	19980724
	EP 1022948	A1	20000802	EP 1998-937129	19980724
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1997-53773P	P	19970725		
	US 1998-121162	A	19980723		
	WO 1998-US15461	W	19980724		

AB The present invention relates generally to immunization methods using recombinant viral vectors. In particular, the invention relates to methods and compns. for immunizing a subject with a nucleic acid mol. encoding an antigen of interest, wherein the nucleic acid mol. is delivered to the subject via a recombinant AAV virion. Recombinant AAV virion encoding ovalbumin gene under control of the cytomegalovirus promoter were constructed and used for transfecting murine melanoma cell line B16 to induce antitumor immunity. Also, ability of the rAAV-ovalbumin to deliver transgene product into the MHC class I pathway was demonstrated.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> e bahjat keith/au

E1 14 BAHJAT K/AU
E2 38 BAHJAT K S/AU
E3 8 --> BAHJAT KEITH/AU
E4 30 BAHJAT KEITH S/AU
E5 2 BAHJAT KHALID S/AU
E6 4 BAHJAT R/AU
E7 3 BAHJAT RENA/AU
E8 2 BAHJAT ZUHAIR/AU
E9 13 BAHJAT ZUHAIR S/AU
E10 2 BAHJERNEJAD M/AU
E11 1 BAHJET/AU
E12 3 BAHJI E/AU

=> s e1-e4 and (nucleic or bacter?)

L5 30 ("BAHJAT K"/AU OR "BAHJAT K S"/AU OR "BAHJAT KEITH"/AU OR "BAHJA T KEITH S"/AU) AND (NUCLEIC OR BACTER?)

=> dup rem 15

PROCESSING COMPLETED FOR L5

L6 12 DUP REM L5 (18 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 12 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1
AN 2006:239172 BIOSIS
DN PREV200600237018
TI Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.
AU Yoshimura, Kiyoshi; Jain, Ajay; Allen, Heather E.; Laird, Lindsay S.; Chia, Christina Y.; Ravi, Sowmya; Brockstedt, Dirk G.; Giedlin, Martin A.; Bahjat, Keith S.; Leong, Meredith L.; Slansky, Jill E.; Cook, David N.; Dubensky, Thomas W.; Pardoll, Drew M.; Schulick, Richard D.

E2 27 HEARST J R/AU
 E3 10 --> HEARST JOHN/AU
 E4 335 HEARST JOHN E/AU
 E5 7 HEARST JOHN EUGENE/AU
 E6 1 HEARST JONENA/AU
 E7 3 HEARST JOSEPH R/AU
 E8 7 HEARST L/AU
 E9 3 HEARST L E/AU
 E10 16 HEARST M/AU
 E11 20 HEARST M A/AU
 E12 2 HEARST M I/AU

=> s e3-e4 and (nucleic or bacter?)
 L7 117 ("HEARST JOHN"/AU OR "HEARST JOHN E"/AU) AND (NUCLEIC OR BACTER?
)

=> dup rem 17
 PROCESSING COMPLETED FOR L7
 L8 106 DUP REM L7 (11 DUPLICATES REMOVED)

=> s l8 and attenuat?
 L9 3 L8 AND ATTENUAT?

=> d bib ab 1-
 YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:100445 CAPLUS
 DN 142:196505
 TI Modified free-living microbes for loading and inducing antigen-presenting cells and uses as vaccines and methods of therapeutic use thereof
 IN Dubensky, Thomas W., Jr.; Brockstedt, Dirk G.; Bahjat, Keith; Hearst, John E.; Cook, David; Luckett, William Stanford
 PA Cerus Corporation, USA
 SO PCT Int. Appl., 291 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009463	A2	20050203	WO 2004-US23881	20040723
	WO 2005009463	A3	20050602		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004197343	A1	20041007	US 2004-773618	20040206
	US 2004228877	A1	20041118	US 2004-773792	20040206
	WO 2005071088	A2	20050804	WO 2004-US44080	20041223
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				

CLMN Number of Claims: 82
ECL Exemplary Claim: 1
DRWN 51 Drawing Page(s)
LN.CNT 7204

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.

=> e cook david/au

E1	5	COOK DARZENS S/AU
E2	5	COOK DAVE/AU
E3	187	--> COOK DAVID/AU
E4	126	COOK DAVID A/AU
E5	2	COOK DAVID ALAN/AU
E6	4	COOK DAVID ALASTAIR/AU
E7	3	COOK DAVID ALLAN/AU
E8	4	COOK DAVID ANTHONY/AU
E9	53	COOK DAVID B/AU
E10	10	COOK DAVID BRANSTON/AU
E11	1	COOK DAVID BRAUSTON/AU
E12	1	COOK DAVID BURFORD/AU

=> e cook david n/au

E1	67	COOK DAVID M/AU
E2	1	COOK DAVID MICHAEL/AU
E3	37	--> COOK DAVID N/AU
E4	1	COOK DAVID NELSON/AU
E5	3	COOK DAVID O/AU
E6	8	COOK DAVID P/AU
E7	2	COOK DAVID PHILIP/AU
E8	39	COOK DAVID R/AU
E9	6	COOK DAVID S/AU
E10	1	COOK DAVID STANLEY/AU
E11	1	COOK DAVID T/AU
E12	28	COOK DAVID W/AU

=> s e3-e4 and (nucleic or bacter?)

L10 26 ("COOK DAVID N"/AU OR "COOK DAVID NELSON"/AU) AND (NUCLEIC OR BACTER?)

=> dup rem 110

PROCESSING COMPLETED FOR L10

L11 18 DUP REM L10 (8 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 18 ANSWERS - CONTINUE? Y/(N):y

L11 ANSWER 1 OF 18 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2006:239172 BIOSIS

DN PREV200600237018

TI Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.

AU Yoshimura, Kiyoshi; Jain, Ajay; Allen, Heather E.; Laird, Lindsay S.;